{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:50:22Z","timestamp":1768272622726,"version":"3.49.0"},"reference-count":58,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00280 and CIBERONC (CB16\/12\/00390 and CB16\/12\/00443)"],"award-info":[{"award-number":["PI16\/00280 and CIBERONC (CB16\/12\/00390 and CB16\/12\/00443)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["SAF2016-75286-R"],"award-info":[{"award-number":["SAF2016-75286-R"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Merck Salud","award":["17-CC-008"],"award-info":[{"award-number":["17-CC-008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Aberrant SRC expression and activation is frequently detected in multiple cancers, and hence, targeting SRC has emerged as a promising therapeutic strategy. Different SRC inhibitors have demonstrated potent anti-tumor activity in preclinical models, although they largely lack clinical efficacy as monotherapy in late-stage solid tumors, including head and neck squamous cell carcinomas (HNSCC). Adequate selection and stratification of patients who may respond to and benefit from anti-SRC therapies is therefore needed to guide clinical trials and treatment efficacy. This study investigates the prognostic significance of active SRC expression in a homogeneous cohort of 122 human papillomavirus (HPV)-negative, surgically treated HNSCC patients. Immunohistochemical evaluation of the active form of SRC by means of anti-SRC Clone 28 monoclonal antibody was specifically performed and subsequently correlated with clinical data. The expression of p-SRC (Tyr419), total SRC, and downstream SRC effectors was also analyzed. Our results uncovered striking differences in the prognostic relevance of SRC expression in HNSCC patients depending on the tumor site. Active SRC expression was found to significantly associate with advanced disease stages, presence of lymph node metastasis, and tumor recurrences in patients with laryngeal tumors, but not in the pharyngeal subgroup. Multivariate Cox analysis further revealed active SRC expression as an independent predictor of cancer-specific mortality in patients with laryngeal carcinomas. Concordantly, expression of p-SRC (Tyr419) and the SRC substrates focal adhesion kinase (FAK) and the Arf GTPase-activating protein ASAP1 also showed specific associations with poor prognosis in the larynx. These findings could have important implications in ongoing Src family kinase (SFK)-based clinical trials, as these new criteria could help to improve patient selection and develop biomarker-stratified trials.<\/jats:p>","DOI":"10.3390\/cancers11111644","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T04:41:27Z","timestamp":1571978487000},"page":"1644","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-0337","authenticated-orcid":false,"given":"Francisco","family":"Hermida-Prado","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Granda-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagore","family":"del-R\u00edo-Ibisate","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. \u00c1ngeles","family":"Villaronga","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2532-5421","authenticated-orcid":false,"given":"Eva","family":"Allonca","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7124-6137","authenticated-orcid":false,"given":"Irati","family":"Garmendia","sequence":"additional","affiliation":[{"name":"Program in Solid Tumors, Center for Applied Medical Research (CIMA); Department of Pathology, Anatomy and Physiology, University of Navarra, and Navarra\u2019s Health Research Institute (IDISNA), 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-1387","authenticated-orcid":false,"given":"Luis M.","family":"Montuenga","sequence":"additional","affiliation":[{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"},{"name":"Program in Solid Tumors, Center for Applied Medical Research (CIMA); Department of Pathology, Anatomy and Physiology, University of Navarra, and Navarra\u2019s Health Research Institute (IDISNA), 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0768-7306","authenticated-orcid":false,"given":"Ren\u00e9","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aitana","family":"Vallina","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"Alvarez-Marcos","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-0890","authenticated-orcid":false,"given":"Juan P.","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5891-9488","authenticated-orcid":false,"given":"Juana M.","family":"Garc\u00eda-Pedrero","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain"},{"name":"Ciber de C\u00e1ncer, CIBERONC, Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMra0707975","article-title":"Recent advances in head and neck cancer","volume":"359","author":"Haddad","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"865819","DOI":"10.1155\/2011\/865819","article-title":"Regulation of Src Family Kinases in Human Cancers","volume":"2011","author":"Sen","year":"2011","journal-title":"J. Signal Transduct."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","article-title":"Src family kinases, key regulators of signal transduction","volume":"23","author":"Parsons","year":"2004","journal-title":"Oncogene"},{"key":"ref_8","first-page":"114","article-title":"Src in cancer: Deregulation and consequences for cell behaviour","volume":"1602","author":"Frame","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","article-title":"c-Src and cooperating partners in human cancer","volume":"6","author":"Ishizawar","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/cncr.23410","article-title":"Epithelial to mesenchymal transition in head and neck squamous carcinoma: Association of Src activation with E-cadherin downregulation, vimentin expression, and aggressive tumor features","volume":"112","author":"Mandal","year":"2008","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ceb.2005.08.007","article-title":"Src and FAK signaling controls adhesion fate and the epithelial-to-mesenchymal transition","volume":"17","author":"Avizienyte","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/MCB.18.5.2571","article-title":"Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2\/mitogen-activated protein kinase: Summation of both c-Src and focal adhesion kinase initiated tyrosine phosphorylation events","volume":"18","author":"Schlaepfer","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.130.2.355","article-title":"c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal growth factor stimulation","volume":"130","author":"Chang","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, W., Liu, Y., and Liao, K. (2011). Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. BMC Cell Biol., 12.","DOI":"10.1186\/1471-2121-12-49"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.emboj.7600588","article-title":"Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities","volume":"24","author":"Onodera","year":"2005","journal-title":"EMBO J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1901765116","article-title":"ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer","volume":"116","author":"Hashimoto","year":"2019","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0959-8049(03)00276-4","article-title":"pp60c-src activation in lung adenocarcinoma","volume":"39","author":"Masaki","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1172\/JCI116200","article-title":"Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer","volume":"91","author":"Talamonti","year":"1993","journal-title":"J. Clin. Invest."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/cncr.22215","article-title":"The role of Src in solid and hematologic malignancies: Development of new-generation Src inhibitors","volume":"107","author":"Alvarez","year":"2006","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tips.2011.11.002","article-title":"Targeting Src family kinases in anti-cancer therapies: Turning promise into triumph","volume":"33","author":"Zhang","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/156800910793605802","article-title":"Is Src a viable target for treating solid tumours?","volume":"10","author":"Elsberger","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1615\/CritRevOncog.v17.i2.20","article-title":"Src kinase inhibitors: Promising cancer therapeutics?","volume":"17","author":"Creedon","year":"2012","journal-title":"Crit. Rev. Oncog."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Scott, A.J., Song, E.K., Bagby, S., Purkey, A., McCarter, M., Gajdos, C., Quackenbush, K.S., Cross, B., Pitts, T.M., and Tan, A.C. (2017). Evaluation of the efficacy of dasatinib, a Src\/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187173"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial","volume":"36","author":"Gore","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73144","DOI":"10.18632\/oncotarget.17113","article-title":"A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM\/2010-04 study","volume":"8","author":"Ocana","year":"2017","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.31234","article-title":"Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56\/07)","volume":"124","author":"Montemurro","year":"2018","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-16-3138","article-title":"Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer","volume":"23","author":"Parseghian","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","article-title":"Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","article-title":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","volume":"3","author":"Green","year":"2009","journal-title":"Mol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.25769","article-title":"Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma","volume":"117","author":"Brooks","year":"2011","journal-title":"Cancer"},{"key":"ref_34","first-page":"249","article-title":"Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)","volume":"31","author":"Fury","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1074\/jbc.271.10.5680","article-title":"A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase","volume":"271","author":"Kawakatsu","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canep.2014.11.003","article-title":"Prevalence of human papillomavirus in laryngeal and hypopharyngeal squamous cell carcinomas in northern Spain","volume":"39","author":"Rodrigo","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/path.2462","article-title":"Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas","volume":"217","author":"Rodrigo","year":"2009","journal-title":"J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.bjc.6604286","article-title":"Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression","volume":"98","author":"Canel","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-811X-12-17","article-title":"High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients","volume":"12","author":"Sato","year":"2014","journal-title":"Cell Commun. Signal"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"eaaf3236","DOI":"10.1126\/scisignal.aaf3236","article-title":"The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression","volume":"10","author":"Becchetti","year":"2017","journal-title":"Sci. Signal"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/modpathol.2012.63","article-title":"Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas","volume":"25","author":"Rodrigo","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.18632\/oncotarget.3071","article-title":"Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas","volume":"6","author":"Veracini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1158\/1078-0432.CCR-07-5226","article-title":"Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma","volume":"14","author":"Koppikar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/1078-0432.CCR-10-0066","article-title":"Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer","volume":"16","author":"Arcaroli","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1158\/1535-7163.MCT-09-1212","article-title":"Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis","volume":"9","author":"Nagaraj","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"85ra47","DOI":"10.1126\/scitranslmed.3002004","article-title":"A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma","volume":"3","author":"Suwaki","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr2332","article-title":"Increased levels of active c-Src distinguish invasive from in situ lobular lesions","volume":"11","author":"Zou","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/hed.21923","article-title":"Significant association of SRC protein expression with the progression, recurrence, and prognosis of oral squamous cell carcinoma in Taiwan","volume":"34","author":"Cheng","year":"2012","journal-title":"Head Neck"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28340","DOI":"10.18632\/oncotarget.8634","article-title":"c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K\/Akt signaling pathway: A new and promising target for NPC","volume":"7","author":"Ke","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hermida-Prado, F., Villaronga, M.A., Granda-D\u00edaz, R., del-R\u00edo-Ibisate, N., Santos, L., Hermosilla, M.A., Oro, P., Allonca, E., Agorreta, J., and Garmendia, I. (2019). The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042. J. Clin. Med., 8.","DOI":"10.3390\/jcm8081157"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/bjc.2014.432","article-title":"Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours","volume":"111","author":"Baro","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4172\/1948-5956.1000009","article-title":"Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function","volume":"1","author":"Ammer","year":"2009","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e90449","DOI":"10.1172\/jci.insight.90449","article-title":"Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer","volume":"2","author":"Bauman","year":"2017","journal-title":"JCI Insight"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nm.2309","article-title":"Combating trastuzumab resistance by targeting SRC, a common nodedownstream of multiple resistance pathways","volume":"17","author":"Zhang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1038\/onc.2011.130","article-title":"Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition","volume":"30","author":"Rexer","year":"2011","journal-title":"Oncogene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-10-0106","article-title":"Inhibition of Src impairs the growth of met-addicted gastric tumors","volume":"16","author":"Bertotti","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1158\/1078-0432.CCR-10-1617","article-title":"Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer","volume":"17","author":"Sen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/etm.2017.4692","article-title":"Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer","volume":"14","author":"Song","year":"2017","journal-title":"Exp. Ther. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/11\/1644\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:16Z","timestamp":1760189356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/11\/1644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["cancers11111644"],"URL":"https:\/\/doi.org\/10.3390\/cancers11111644","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]}}}